Dr. Nick Jacob currently serves as a Chief Scientific Officer to ARMR Sciences, Inc. Most recently, Dr. Jacob served as Senior Research Scientist at Cessation Therapeutics, a clinical-stage startup developing a monoclonal antibody against fentanyl and its derivatives. As a founding team member, he successfully transitioned the program from a licensed academic project into a clinical asset in Phase 1 trials. Prior to that, Nick trained under Dr. Kim Janda at Scripps Research contributing to the derivation and testing of multiple bioconjugate vaccines directed against fentanyl, nicotine and cocaine while achieving his PhD in Medicinal and Pharmaceutical Chemistry. His research experience spans from developing biologics and small molecules for therapeutic purposes to advising on development strategies and navigating federal funding mechanisms. He has been a primary or named co-author on multiple scientific publications in high impact journals concerning prophylactic and therapeutic product development paradigms for treating substance use disorders.